This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
by Zacks Equity Research
Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.
Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?
by Zacks Equity Research
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company News for Jan 3, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, RCL, NVDA, MRK
Why the Market Dipped But Moderna (MRNA) Gained Today
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.
Stock Market News for Dec 28, 2023
by Zacks Equity Research
Wall Street closed higher on Wednesday, with the S&P 500, the Dow and the Nasdaq notching their longest winning streak since 2017.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma
by Zacks Equity Research
Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.
Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study
by Zacks Equity Research
Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
by Kinjel Shah
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.
Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy
by Zacks Equity Research
The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.
Why Is Iovance Biotherapeutics (IOVA) Up 53% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
by Zacks Equity Research
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
by Zacks Equity Research
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.
Exploring Analyst Estimates for Moderna (MRNA) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2023.
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.